RedHill Biopharma Ltd.

RDHL • Drug Manufacturers - Specialty & Generic

$0.52

▲ +0.01 (+1.99%)

Current price

EarningsLatest report: Dec 31, 2025

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$932,872.717

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.25Weak liquidity · 0.34Negative growth trendWeak profitability

Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Dec 31, 2025, 12:00 AM UTCLast profile update: Sep 2, 2026, 12:17 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.52

Change1.99%

Shares Out1.80M

Market Cap$932.87K

Enterprise Value$-3.04M

52W Range0.57 - 2.79

Beta4.90

P/E-0.10

P/S0.10

P/B0.22

P/FCF-0.11

EV/Sales-0.32

Price$0.52

Change1.99%

Shares Out1.80M

Market Cap$932.87K

Enterprise Value$-3.04M

52W Range0.57 - 2.79

Beta4.90

P/E-0.10

P/S0.10

P/B0.22

P/FCF-0.11

EV/Sales-0.32

EV/EBITDA0.38

EV/FCF0.37

Earnings Yield-998.31%

FCF Yield-880.18%

Dividend Yield0.00%

Gross Margin100.00%

Oper. Margin-27.65%

Profit Margin-150.00%

Debt/Eq0.25

Current Ratio0.34

Quick Ratio0.34

Volume3.69M

Avg Volume163.55K

EPS Surprise-170.00

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

39/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

58/100

Why this score▼

Manageable debt level · 0.25Weak liquidity · 0.34Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

RDHL

Analyst sentiment

Based on 10 analyst votes · 2026-10-20

100/100

Bullish

Hold

Bearish

Company Overview

IPO: 1/7/2013

Industry: Drug Manufacturers - Specialty & Generic

P/B i: 0.22

Debt / Equity i: 0.25

Operating Margin: -2765.38%

Net Margin: -150.00%

ROE i: -

ROIC: -

Financial Health

Score8 / 20

Debt / Equity: 0.25

Current Ratio: 0.34

Quick Ratio: 0.34

Status: Moderate

Warnings

Weak Liquidity
Weak quick ratio

Insider Transactions

Recent executive and insider activity

⚠ 2 high-volume insider sells detected

Raday Gilead

Transaction: 07/10/2026

BUY

Change

+28,150,000

Price

Not reported

Filing

07/13/2026

Type

BUY

Raday Gilead

Transaction: 07/10/2026

SELL

Change

-14,130,000

Price

$0.00

Filing

07/13/2026

Type

SELL

Raday Gilead

Transaction: 04/06/2026

BUY

Change

+30,780,000

Price

Not reported

Filing

04/22/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Raday Gilead	BUY	+28,150,000	Not reported	07/10/2026	07/13/2026
Raday Gilead	SELL	-14,130,000	$0.00	07/10/2026	07/13/2026
Raday Gilead	BUY	+30,780,000	Not reported	04/06/2026	04/22/2026
Raday Gilead	SELL	-15,740,000	$0.00	04/06/2026	04/22/2026
Tsimchi Ofer	OTHER	+180,000	Not reported	03/18/2026	03/19/2026
Tsimchi Ofer	OTHER	+36,440,000	Not reported	03/18/2026	03/19/2026
Tsimchi Ofer	OTHER	0	Not reported	03/18/2026	03/19/2026
Ben-Asher Dror	OTHER	+1,100,000	Not reported	03/18/2026	03/18/2026
Ben-Asher Dror	OTHER	+103,360,000	Not reported	03/18/2026	03/18/2026
Ben-Asher Dror	OTHER	0	Not reported	03/18/2026	03/18/2026
Cabilly Shmuel	OTHER	+180,000	Not reported	03/18/2026	03/18/2026
Cabilly Shmuel	OTHER	+30,630,000	Not reported	03/18/2026	03/18/2026
Cabilly Shmuel	OTHER	0	Not reported	03/18/2026	03/18/2026
Frish Adi	OTHER	+750,000	Not reported	03/18/2026	03/18/2026
Frish Adi	OTHER	+62,800,000	Not reported	03/18/2026	03/18/2026
Frish Adi	OTHER	0	Not reported	03/18/2026	03/18/2026
Goldberg Guy Joel	OTHER	+600,000	Not reported	03/18/2026	03/18/2026
Goldberg Guy Joel	OTHER	+555,310,000	Not reported	03/18/2026	03/18/2026
Goldberg Guy Joel	OTHER	0	Not reported	03/18/2026	03/18/2026
Ingber Razi	OTHER	+230,000	Not reported	03/18/2026	03/18/2026

About the Company

RedHill Biopharma Ltd.

RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.

Source - link

Peers

AKAN BGMS BNBX CNSP FLGC GCTK IMCC JAGX MSPR SXTP

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma

TEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

PRNewsWire

Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL)

Redhill Biopharma (NASDAQ: RDHL - Get Free Report) and Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Valuation and Earnings This table compares Redhill

Defense World

RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results

Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal (GI) brands that generated $37.5 million in 2025 net sales under Ferring Pharmaceuticals ("Ferring"), an advanced late-stage pipeline and a fully-controlled commercial infrastructure with capacity for portfolio expansion TEL AVIV, Israel and RALEIGH, N.C., Sept. 30, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.

PRNewsWire

Critical Analysis: Redhill Biopharma (NASDAQ:RDHL) versus Novartis (NYSE:NVS)

Novartis (NYSE: NVS - Get Free Report) and Redhill Biopharma (NASDAQ: RDHL - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Profitability This table compares Novartis and Redhill Biopharma's net

Defense World

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill's commercial GI business The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill's control, with a significantly stronger liquidity position and provides additional growth and expansion opportunities Under the terms of the agreement, RedHill obtained the exclusive commercialization rights for an upfront payment to Ferring of $12 million plus potential future milestones and tiered royalties. The $12 million upfront payment is fully funded through the previously announced $18 million Talicia divestment, with RedHill securing exclusive global and U.S. commercialization rights to Ferring's Rebyota® and Clenpiq®, respectively - two synergistic, revenue-generating, FDA-approved GI drugs Rebyota is a proprietary, first and only single-dose FDA-approved Fecal Microbiota Transplant (FMT for prevention of recurrent C.

PRNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2024-08-29	-30	-200	-170
2024-02-12	-0.03	-0.2	-0.17
2022-11-07	-0.3	-2	-1.7
2022-06-23	-4	-3	1
2022-03-17	-4	-5	-1
2021-11-30	-4.8	-4.6	0.2
2021-08-26	-4	-6.2	-2.2
2021-05-27	-4.6	-5.3	-0.7
2021-03-18	-4.5	-7	-2.5
2020-11-12	-2.2	-5	-2.8
2020-08-13	-1.4	-4.5	-3.1
2020-05-27	-3.8	-4.9	-1.1